Table 3.
Regression Analyses and Analog to ANOVA Examining Moderators of Treatment Efficacy, Treatment Response, and Remission for CBT and SRI Trials
| CBT Trials versus Non-active comparisons | Treatment Efficacy (n=7) | Treatment Response (n=7) | Symptom Remission (n=7) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||
| Study Characteristics | B | SE | z | p | B | SE | z | p | B | SE | z | p |
|
|
||||||||||||
| Mean Participant Age | −0.05 | 0.09 | −0.50 | 0.61 | −0.09 | 0.12 | −0.82 | 0.41 | −0.16 | 0.16 | −1.01 | 0.31 |
| Percentage of comorbid TS or CTD | 0.05 | 0.03 | 1.49 | 0.14 | <0.01 | 0.05 | 0.01 | 0.99 | 0.09 | 0.06 | 1.47 | 0.14 |
| Percentage of comorbid ADHD | −0.01 | 0.02 | −0.40 | 0.69 | −0.01 | 0.03 | −0.33 | 0.74 | 0.03 | 0.04 | 0.83 | 0.41 |
| Percentage of comorbid Depressive Disorders | −0.06 | 0.05 | −1.21 | 0.22 | −0.03 | 0.06 | −0.58 | 0.56 | −0.05 | 0.08 | −0.63 | 0.53 |
| Percentage of comorbid Anxiety Disorders | 0.03 | 0.01 | 2.59 | 0.01 | 0.04 | 0.02 | 2.41 | 0.02 | 0.02 | 0.03 | 0.60 | 0.55 |
| Baseline CY-BOCS Symptom Severity | −0.09 | 0.23 | −0.40 | 0.69 | −0.20 | 0.16 | −1. 24 | 0.21 | 0.54 | 0.33 | 1.66 | 0.10 |
| Percentage of participants on a SRI | −0.00 | 0.01 | −0.06 | 0.95 | −0.01 | 0.01 | 0.70 | 0.48 | −0.01 | 0.02 | −0.67 | 0.50 |
| Number of 1-hour Therapy Sessions | 0.13 | 0.05 | 2.75 | 0.005 | 0.08 | 0.10 | 0.84 | 0.40 | 0.23 | 0.11 | 2.01 | 0.04 |
| Percentage of Active Treatment Dropout | −0.07 | 0.03 | −2.57 | 0.01 | −0.05 | 0.06 | −0.97 | 0.33 | −0.09 | 0.05 | −1.79 | 0.07 |
| Methodological Quality | −0.09 | 0.07 | −1.29 | 0.20 | −0.11 | 0.06 | −1.84 | 0.07 | 0.14 | 0.14 | 0.96 | 0.34 |
| Q | (df) | p | Q | (df) | p | Q | (df) | p | ||||
|
|
|
|
||||||||||
| Treatment Subtype (ERP vs. CT) | 0.08 | 1 | 0.78 | 0.55 | 1 | 0.46 | 0.34 | 1 | 0.56 | |||
| Outcome Measure | NA | NA | NA | 1.04 | 1 | 0.31 | 1.39 | 1 | 0.24 | |||
|
| ||||||||||||
| CBT Trials versus Active Comparisons | Treatment Efficacy (n=3) | Treatment Response (n=3) | Symptom Remission (n=3) | |||||||||
|
|
||||||||||||
| Study Characteristics | B | SE | z | p | B | SE | z | p | B | SE | z | p |
|
|
||||||||||||
| Mean Participant Age | −0.10 | 0.12 | −0.79 | 0.43 | 0.05 | 0.08 | 0.62 | 0.53 | 0.05 | 0.12 | 0.39 | 0.70 |
| Percentage of comorbid TS or CTD | 0.10 | 0.04 | 2.67 | 0.01 | 0.02 | 0.04 | 0.46 | 0.64 | −0.03 | 0.05 | −0.61 | 0.54 |
| Percentage of comorbid ADHD | −0.06 | 0.15 | −0.37 | 0.71 | −0.08 | 0.08 | −1.00 | 0.32 | 0.04 | 0.11 | 0.40 | 0.69 |
| Percentage of comorbid Depressive Disorders | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Percentage of comorbid Anxiety Disorders | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Baseline CY-BOCS Symptom Severity | −0.16 | 0.22 | 0.71 | 0.48 | 0.10 | 0.12 | 0.87 | 0.39 | −0.08 | 0.17 | −0.51 | 0.61 |
| Percentage of participants on a SRI | −0.06 | 0.04 | −1.67 | 0.10 | −0.02 | 0.03 | −0.64 | 0.52 | 0.02 | 0.04 | 0.58 | 0.56 |
| Number of 1-hour Therapy Sessions | −0.10 | 0.12 | −0.82 | 0.41 | 0.05 | 0.08 | 0.60 | 0.55 | 0.05 | 0.12 | 0.40 | 0.69 |
| Percentage of Active Treatment Dropout | −0.04 | 0.05 | −0.79 | 0.43 | −0.02 | 0.03 | −0.85 | 0.40 | 0.02 | 0.04 | 0.52 | 0.61 |
| Methodological Quality | −0.07 | 0.07 | 0.96 | 0.34 | 0.03 | 0.04 | 0.79 | 0.43 | −0.03 | 0.06 | −0.54 | 0.59 |
| Q | (df) | p | Q | (df) | p | Q | (df) | p | ||||
|
|
|
|
||||||||||
| Treatment Subtype (ERP vs. CT) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Outcome Measure | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
|
| ||||||||||||
| SRI Trials versus Non-Active Comparisons | Treatment Efficacy (n=11) | Treatment Response (n=7) | Symptom Remission (n=3) | |||||||||
|
|
||||||||||||
| Study Characteristics | B | SE | z | p | B | SE | Z | p | B | SE | z | p |
|
|
||||||||||||
| Mean Participant Age | 0.08 | 0.06 | 1.26 | 0.21 | 0.18 | 0.12 | 1.44 | 0.15 | −0.29 | 1.42 | −0.21 | 0.83 |
| Percentage of comorbid TS or CTD | < 0.01 | 0.02 | 0.03 | 0.97 | −0.01 | 0.03 | −0.33 | 0.74 | 0.10 | 0.06 | 1.80 | 0.07 |
| Percentage of comorbid ADHD | < −0.01 | 0.02 | −0.31 | 0.76 | −0.03 | 0.02 | −1.22 | 0.22 | 0.09 | 0.09 | 0.99 | 0.32 |
| Percentage of comorbid Depressive Disorders | −0.01 | 0.02 | −0.47 | 0.63 | <0.01 | 0.02 | 0.19 | 0.85 | −0.03 | 0.08 | −0.34 | 0.73 |
| Percentage of comorbid Anxiety Disorders | < −0.01 | 0.01 | −0.26 | 0.79 | 0.01 | 0.01 | 0.74 | 0.46 | NA | NA | NA | NA |
| Baseline CY-BOCS Symptom Severity | < 0.01 | 0.05 | 0.09 | 0.93 | 0.10 | 0.09 | 1.14 | 0.26 | −0.20 | 0.96 | −0.21 | 0.84 |
| Percentage of Active Treatment Dropout | −0.01 | 0.01 | −1.40 | 0.16 | −0.01 | 0.01 | −0.93 | 0.35 | −0.02 | 0.07 | −0.24 | 0.81 |
| Methodological Quality | −0.02 | 0.02 | −1.44 | 0.15 | −0.06 | 0.03 | −2.01 | 0.04 | 0.34 | 0.18 | 1.91 | 0.06 |
| Q | (df) | p | Q | (df) | p | Q | (df) | p | ||||
|
|
|
|
||||||||||
| Treatment Subtype (SSRI v. CMI) | 2.55 | 1 | 0.11 | 2.85 | 1 | 0.09 | NA | NA | NA | |||
| Outcome Measure | 1.79 | 1 | 0.18 | 0.21 | 1 | 0.64 | 3.66 | 2 | 0.16 | |||
Note: TS = Tourette Syndrome, CTD = Chronic Tic Disorder, CY-BOCS = Children’s Yale-Brown Obsessive-Compulsive Scale, SRI = Serotonin Reuptake Inhibitor, NA = Not Applicable,